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Dear Sirs,
We were interested to read the paper by Navarro-Fernández and colleagues regarding antithrombin Dublin (p.Val30Glu) and its capacity to cause transient antithrombin deficiency (1) . Antithrombin Dublin was first described by one of us in 1987 when it was identified as part of a study that aimed to determine the effects of asparaginase therapy on the different plasma isoforms of antithrombin that can be distinguished by isoelectric focusing. The Dublin variant was found to be more negatively charged when compared with normal antithrombin (2). Sequencing of SERPINC1 encoding antithrombin subsequently revealed a single nucleotide variation predicting a p.Val30Glu substitution in the signal peptide of antithrombin which redirects signal peptidase cleavage to a site two amino acids into the mature protein and results in removal of the N-terminal dipeptide from antithrombin (3).
Of note, while none of the heterozygous carriers of the Dublin variant identified in the original study had a history of thrombosis at the time of investigation, in our subsequent study we reported the Dublin variant in a patient with a history of spontaneous deep vein thrombosis and pulmonary embolus at age 41 and the presence of anti-IIa and anti-Xa Navarro-Fernández et al (1) observed that recombinant antithrombin Dublin adopted a hyperstable conformation of reduced activity when it was expressed in HEK cells. This led them to speculate that the p.Val30Glu mutation facilitates the formation of disulphidelinked polymers of antithrombin, similar to those reported for antithrombins Wibble and Rouen VI, two variants caused by mutations that facilitate the conversion of antithrombin to its latent form and the development of antithrombin deficiency under conformational stress conditions such as pyrexia (4, 5) . However, they did not identify the factors that might have triggered the conformation stress conditions in the symptomatic carriers of the Dublin variant in their study. 3 We recently identified antithrombin Dublin in a patient who developed a pulmonary embolism during pregnancy. Her thrombin-based antithrombin levels (Berichrom, Sysmex UK) on the ACL TOP analyser (Werfen UK) were initially reduced (0.72, 0.69 and 0.73IU/mL) but increased and indeed normalised after delivery (1.04, 0.92 and 0.86IU/mL).
Antithrombin antigen (ELISA) agreed well with antithrombin activity levels during pregnancy (0.75, 0.76, 0.74IU/mL) and after delivery (0.98IU/mL). Our adult reference ranges for antithrombin activity and antigen are 0.85-1.31IU/mL and 0.83-1.24IU/mL, respectively, and our antithrombin activity inter-assay coefficient of variation (CV) is 2.5% at an antithrombin Dublin. However, the number of cases reported, for whom antithrombin levels are also available, is small, and we cannot rule out an assay-specific effect. Interestingly, Puurunen et al (7) identified the Dublin variant in four members of a Finnish family, two of whom had clear type II deficiency while the other two had normal levels of antithrombin activity and antigen. Measurement of the antithrombin activity results in the two carriers with type II deficiency using five different assays showed concordance in the two carriers with type II deficiency (7). In the study by Navarro-Fernández et al (1) , there were likely to be differences in the assays used to diagnose antithrombin deficiency at the hospital of origin, and the central reference laboratory. The results seen in our patient would suggest however, that the differences they observed were genuine and not due to assay variation.
